{
    "nct_id": "NCT03989115",
    "official_title": "Ph1b/2 Open-Label,Multicenter Dose-Esc & Dose-Exp Study of Combo RMC4630 & Cobimetinib in Participants w/Relapsed/Refractory Solid Tumors & Ph1b Study of RMC4630 w/Osimertinib in Participants w/EGFR Mutation+,Locally Adv or Meta NSCLC",
    "inclusion_criteria": "* Age ≥18 years\n* For RMC-4630 + Cobimetinib only - Participants who have advanced solid tumors that have failed, are intolerant to, or are considered ineligible for standard of care anti-cancer treatments including approved drugs for oncogenic drivers in their tumor type.\n* For RMC-4630 + Osimertinib only - Locally advanced or metastatic EGFR mutant NSCLC not amenable to curative surgery or radiotherapy\n* For RMC-4630 + Cobimetinib only - Participants must have one of the following genotypic aberrations: KRAS mutations and amplifications, BRAF Class 3 mutations, or NF1 LOF mutations\n* For RMC-4630 + Osimertinib only - Evidence of radiological documentation of progression with osimertinib monotherapy or an osimertinib containing regimen. Participants should not be considered a current candidate for 1st generation EGFR TKI's by the investigator.\n* Eastern Cooperative Oncology Group (ECOG) performance status of ≤1\n* Adequate hematological, hepatic, and renal function\n* Capable of giving signed informed consent form (ICF). Willing and able to compile with study requirements and restrictions\n* Life expectancy >12 weeks\n* Female of childbearing potential and males with partners of childbearing potential must comply with effective contraception criteria .\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Primary central nervous system (CNS) tumors.\n* Known or suspected leptomeningeal or brain metastases or spinal cord compression.\n* For RMC-4630 + osimertinib arm only - Known or suspected Small cell, squamous, or pleomorphic lung transformations\n* Clinically significant cardiac disease\n* Active, clinically signiﬁcant interstitial lung disease or pneumonitis\n* History or current evidence of retinal pigment epithelial detachment (RPED), central serous retinopathy, retinal vein occlusion (RVO), or predisposing factors to RPED or RVO\n* Known HIV infection or active/chronic hepatitis B or C infection.\n* Any other unstable or clinically signiﬁcant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy\n* Females who are pregnant or breastfeeding",
    "miscellaneous_criteria": ""
}